FOXO4-DRI

FOXO4-DRI is a D-retro-inverso peptide developed to interfere with the FOXO4-p53 interaction involved in survival of some senescent cells. A 2025 structural study found that the peptide binds the p53 transactivation domain in a molecular system. Binding and senescent-cell apoptosis in models do not establish selective action or clinical benefit in people. Baar et al., 2017 · Bourgeois et al., 2025

What the studies tested

The original FOXO4-DRI report by Baar and colleagues in 2017 studied senescent cells, chemotoxicity models, and naturally aged or accelerated-aging mice. It reported senescent-cell apoptosis and improvements in selected mouse fitness, fur and renal measures. These were laboratory and animal endpoints, not a human longevity trial. PMID 28340339

A separate 2020 study tested senescent Leydig cells and naturally aged male mice, reporting higher testosterone measures after FOXO4-DRI in the mice. Its authors said the mechanism of that increase and its duration remained unresolved. The human testis observations in that paper were laboratory observations, not administration of FOXO4-DRI to people. PMID 31959736

In 2025, a keloid study reported apoptosis in senescent fibroblast and human-tissue organ-culture models. Organ culture is not a clinical treatment study. A paper published January 15, 2026 in a journal volume labeled 2025 studied senescent endothelial cells and naturally aged and induced-aging mice; it reported mouse aortic and laboratory endothelial outcomes. Neither paper establishes keloid treatment or vascular benefit in humans. PMID 39994346 · PMID 41625068

Why model context matters

The direction of a senolytic result is not uniform across tissues and disease models. In a 2023 pulmonary-hypertension study, senescent-cell removal worsened pulmonary hemodynamics in several animal models; one comparison included FOXO4-DRI in mice. That finding does not quantify human risk, but it prevents a general claim that clearing senescent cells is consistently beneficial or harmless. PMID 36515093

A 2026 review states that FOXO4-DRI has not been clinically validated and identifies delivery, pharmacokinetic, long-term toxicology and p53-dependent tumor-surveillance questions. These are unresolved research questions, not demonstrated adverse events in people. PMID 42510573

Interpretation

The cited evidence supports a FOXO4-p53 interaction and model-specific senescent-cell effects. It does not show that FOXO4-DRI clears senescent cells throughout a human body, restores human organ function, extends human lifespan, or has an established safe clinical use. Evidence strength for human outcomes remains very low.

This dossier summarizes research. It is not medical advice or guidance for self-treatment.